Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label PET biodistribution study of [89Zr]Zr-BI 905677 in advanced solid tumors with RNF43 mutation or R-Spondin fusion
NL-OMON49457Phase 1Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2020
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 905677 and Zr-BI 905677 in Nonhematologic neoplasms (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Relative change in tumor SUVpeak from baseline to post-BI 905677 dosing. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
BI 905677Zr-BI 905677
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON49457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49457.